4.3 Article

A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment

Journal

JOURNAL OF NEURAL TRANSMISSION
Volume 122, Issue 3, Pages 465-475

Publisher

SPRINGER WIEN
DOI: 10.1007/s00702-014-1267-2

Keywords

Major depressive disorder; Citalopram; Glutamatergic; Monoaminergic; Molecular pathways

Funding

  1. NIMH [N01MH90003]

Ask authors/readers for more resources

The efficacy of current antidepressant (AD) drugs for the treatment of major depressive disorder (MDD) lays behind expectations. The correct genetic differentiation between severe and less severe cases before treatment may pave the way to the most correct clinical choices in clinical practice. Genetics may pave the way such identification, which in turns may provide perspectives for the synthesis of new ADs by correcting the molecular unbalances that differentiate severe and less severe depressive patients. We investigated 1,903 MDD patients from the STAR*D study. Outcome was the number of severe depressive records, defined as a Quick Inventory of Depressive Symptomatology (QIDS)-Clinician rated (C) total score >15, corrected for the number of observations for each patient during the first 14 weeks of citalopram treatment. Predictors were the genetic variations harbored by genes involved in the glutamatergic-monoaminergic interplay as defined in a previous work published by our group. Clinical and socio-demographic stratification factor analyses were taken in cases and controls. Covariated linear regression was the statistical model for the analysis. SNPs were analyzed in groups (molecular pathway analysis) testing the hypothesis that the distribution of significant (p < 0.05) associations between SNPs and the outcome segregates within each pathway/gene subset. The best associated results are relative to two signle SNPs, (rs7744492 in AKAP12 p = 0.0004 and rs17046113 in CAMK2D p = 0.0006) and a molecular pathway (cAMP biosynthetic process p = 0.005). After correction for multitesting, none of them resulted to be significantly associated. These results are consistent with previous findings in literature and further stress that the molecular mechanisms targeted by current ADs may not be the key biological variables that differentiate severe from mild depression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Music to improve sleep quality in adults with depression-related insomnia (MUSTAFI): randomized controlled trial

Helle Nystrup Lund, Inge Nygaard Pedersen, Agnieszka M. Heymann-Szlachcinska, Maryla Tuszewska, Gustav Bizik, Jens Ivar Larsen, Antonio Drago, Eszter Kulhay, Anelia Larsen, Helle Ostermark Sorensen, Bettina Gronbech, Lars Rye Bertelsen, Jan Brink Valentin, Jan Mainz, Soren Paaske Johnsen

Summary: This study examined the efficacy of music intervention in depression-related insomnia. The results showed that music intervention can significantly improve sleep quality and well-being. However, the effects of music intervention decreased after the intervention was terminated.

NORDIC JOURNAL OF PSYCHIATRY (2023)

Review Psychiatry

Mental fatigue in individuals with psychiatric disorders: a scoping review

Kristina Mozuraityte, Agne Stanyte, Naomi A. Fineberg, Alessandro Serretti, Julija Gecaite-Stonciene, Julius Burkauskas

Summary: This study conducted a scoping review of published literature to examine the relationship between mental fatigue and various psychiatric disorders. The findings suggest that mental fatigue is studied in mood disorders, anxiety disorders, obsessive-compulsive disorder, and obsessive-compulsive personality disorder. Cognitive factors such as unhelpful beliefs about sleep and symptom-focussed rumination, as well as personality risk factors, were found to be relevant in predicting mental fatigue symptoms. Further investigation is needed to explore mental fatigue in adult psychiatric samples.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Psychiatry

Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting

Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri

Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Article Pharmacology & Pharmacy

Unhealthy lifestyle impacts on biological systems involved in stress response: hypothalamic-pituitary-adrenal axis, inflammation and autonomous nervous system

Laura Mandelli, Yuri Milaneschi, Sarah Hiles, Alessandro Serretti, Brenda W. Penninx

Summary: An unhealthy lifestyle plays a crucial role in the development and progression of chronic disorders, and it may also affect biological systems involved in stress response. Using data from the Netherlands Study of Depression and Anxiety, researchers calculated a global index of unhealthy lifestyle based on five self-reported habits. They found that the index was associated with hyperactivity of the hypothalamus-pituitary-adrenal axis and increased inflammation, indicating that unhealthy habits increase biological stress. The use of drugs also impacted the autonomic nervous system activity.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Fine-tuning of psychopharmacological treatments

Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

The challenge of managing difficult to treat psychiatric conditions

Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Clinical Neurology

Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns

Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti

Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Review Genetics & Heredity

Genetics of nonpharmacological treatments of depression

Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, Chiara Fabbri, Alessandro Serretti

Summary: Nonpharmacological treatments for depression show effectiveness and tolerability in certain patients with diverse response. Genetic variables associated with treatment efficacy need to be examined to assist treatment selection. Most studies using candidate gene approach yielded poorly replicated findings due to small sample sizes, while a few methylome-wide and genome-wide association studies (GWASs) provided interesting results with the use of polygenic risk scores in small samples of electroconvulsive therapy (ECT) and cognitive-behavioral therapy. Further GWAS with larger sample sizes, such as the gen-ECT-ic consortium, can enhance our understanding of the genetic factors underlying treatment response in nonpharmacological therapies for depression.

PSYCHIATRIC GENETICS (2023)

Article Environmental Sciences

Air Pollution and Aeroallergens as Possible Triggers in Preterm Birth Delivery

Enrico Cocchi, Valeria Bellisario, Francesco Cresi, Claudio Plazzotta, Claudio Cassardo, Consolata Siniscalco, Licia Peruzzi, Roberto Bono

Summary: The study analyzed data from 2015 to 2017 and found a significant association between increased levels of chemical pollutants (PM2.5 and O-3) and biological pollutants (aeroallergens) in the week before delivery and the risk of preterm birth. This suggests that air pollution may induce preterm birth by triggering acute inflammation in pregnant women.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2023)

Editorial Material Pharmacology & Pharmacy

In search of clinical targets for suicide prevention in major depressive disorder

Paolo Olgiati, Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Interplay of environmental and clinical factors in psychiatric disorders

Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Chemistry, Analytical

Volumetric absorptive microsampling for the therapeutic drug monitoring of psychiatric patients treated with cariprazine

Jaime Millan-Santiago, Rosalba Vitagliano, Fortunata Mondella, Roberto Mandrioli, Roccaldo Sardella, Rafael Lucena, Tomaz Vovk, Soledad Cardenas, Federico Boaron, Alessandro Serretti, Carmine Petio, Michele Protti, Laura Mercolini

Summary: In this study, a bioanalytical method using volumetric absorptive microsampling (VAMS) was developed and validated for therapeutic drug monitoring (TDM) of psychiatric patients under cariprazine treatment. The VAMS-UHPLC-MS methodology showed satisfactory results and was proven to be a useful alternative to cariprazine plasma analysis in clinical practice.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)

Review Neurosciences

Anhedonia and Depressive Disorders

Alessandro Serretti

Summary: Anhedonia is a core symptom of depression and other psychiatric disorders, referring to a lack of pleasure or reward. It is not only a psychological distress but also encompasses a range of reward processing deficits. Anhedonia is a relevant risk factor for suicidal behaviors and may operate independently of the severity of depressive episodes. It has also been associated with inflammation, which can have a reciprocal detrimental effect on depression. The neurophysiological bases of anhedonia mainly involve changes in striatal and prefrontal areas, with dopamine playing a key role as the neurotransmitter involved. Anhedonia is believed to have a significant genetic component and polygenic risk scores may be a tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants have shown limited benefit in treating anhedonia, also considering their potential to worsen anhedonia in some individuals. Other treatments such as agomelatine, vortioxetine, ketamine, and transcranial magnetic stimulation may be more effective. Psychotherapy, particularly cognitive-behavioral therapy and behavioral activation, is widely supported as beneficial for anhedonia. In conclusion, evidence suggests that anhedonia is partially independent from depression and requires careful evaluation and targeted treatment.

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2023)

Meeting Abstract Psychiatry

Genetic underpinnings of YMRS and MADRS scores variations in a bipolar sample

M. Calabro, C. Crisafulli, A. Drago

EUROPEAN PSYCHIATRY (2023)

Meeting Abstract Psychiatry

The effect of music to improve sleep quality in depression related insomnia

H. N. Lund, I. N. Pedersen, A. Heymann-Szlachcinska, M. Tuszewska, G. Bizik, J. I. Larsen, A. Drago, E. Kulhay, A. Larsen, H. O. Sorensen, B. Gronbech, L. R. Bertelsen, J. B. Valentin, J. Mainz, S. P. Johnsen, N. Hannibal, R. MacDonald

EUROPEAN PSYCHIATRY (2023)

No Data Available